DiabetologyNews.net

Diabetology Xagena

Search results for "Byetta"

Exenatide ( Byetta ) reduced HbA1c with no weight gain and no increased incidence of hypoglycemia in patients with type 2 diabetes failing to achieve glycemic control with Metformin. Exenatide is t ...


FDA ( Food and Drug Administration ) has approved Exenatide ( Byetta ), also known as synthetic exendin-4, injection as adjunctive therapy to improve blood sugar control in patients with type 2 diabet ...


Results from a study indicating that Exenatide ( Byetta ) injection showed sustained improvements in blood glucose control and progressive weight reduction through a year and a half of therapy for peo ...


Research suggests that the investigational drug Vildagliptin ( Galvus ) improves the function of pancreatic islets in both animals and humans. Improved pancreatic islet function is a long-standing go ...


Results from a study indicate that Exenatide injection ( Byetta ) improves blood glucose levels as effectively as Insulin Glargine ( Lantus ) for patients with type 2 diabetes failing to achieve accep ...


The study was designed to assess the safety, tolerability and pharmacokinetics of Exenatide ( Byetta ) LAR (long-acting release ) given once a week. After 15 weeks, both doses of Exenatide LAR were ...


A two-year study has shown that Exenatide ( Byetta ) injection sustained improvements in blood glucose control and reduced body weight in people with type 2 diabetes who previously did not achieve ade ...


Researchers at University of Illinois at Chicago ( UIC ) have modified the procedure for islet cell transplantation and achieved insulin independence in diabetes patients with fewer but better-functio ...


Researchers at University of Illinois at Chicago ( UIC ) have modified the procedure for islet cell transplantation and achieved insulin independence in diabetes patients with fewer but better-functio ...


Liraglutide ( Victoza ) once daily is substantially better at controlling blood glucose in type 2 diabetes than is twice-daily Exenatide ( Byetta ). These are the findings of the LEAD-6 study.Liraglut ...


The EMA ( European Medicines Agency ) is investigating findings by a group of independent academic researchers that suggest an increased risk of pancreatitis ( inflammation of the pancreas ) and preca ...


Glucagon-like peptide-1 receptor agonists Exenatide ( Byetta ) and Liraglutide ( Victoza ) have been shown to improve glycaemic control and reduce bodyweight in patients with type 2 diabetes.The effic ...


Sanofi-Aventis has announced that Lixisenatide ( Lyxumia ) once-daily achieved primary efficacy endpoint and fewer hypoglycemias versus Exenatide ( Byetta ) twice-daily. The GetGoal-X Phase III stu ...